

SHREE RAM PROTEINS LTD.

Reg Off: B-206, The Imperial Heights, Opp. Big Bazaar, 150 Ft. Ring Road, Rajkot-360005, Gujarat, INDIA. Ph. +91 281 2581152

Fact : Survey No. 54 P, N.H. 27A, Nr. Pan Agri Exports At. Bhunava, Ta. Gondal, Dist. Rajkot - 360311, Gujarat (INDIA) Ph.: +91 2825 280634 / 35

E-mail: shree_ramcotton@yahoo.com, info@shreeramproteins.com
web: www.shreeramproteins.com
Corporate Identity Number (CIN) L01405GJ2008PLC054913



To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra East, Mumbai – 400051

Dear Sir,

Sub: Outcome of board meeting held on today i.e. On November 08, 2023, In Terms Of Second Proviso to Regulation 30(6) Of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Shree Ram Proteins Limited (Symbol:-SRPL, ISIN:-INE008Z01020)

In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held on today, i.e. on November 08, 2023, at the Registered Office of the Company which was commenced at 06:00 PM and concluded at 06:30 PM at the registered office of the company situated at Imperial Heights Tower-B, Second Floor, Office No. B-206, 150 Ft Ring Road, Opp big Bazar, Rajkot-360005, Gujarat, India, to have;

- 1. Considered, approved and taken on record the Unaudited Standalone financial result of the Company for the Quarter and Half year ended on September 30, 2023, and
- 2. Statement of Assets and Liabilities.
- 3. Cash Flow Statement.
- 4. Considered and approved all other business as per agenda circulated

Further, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are enclosing herewith the Standalone Unaudited Financial Results for the Quarter and Half year ended September 30, 2023 and Limited Review Report issued by Statutory Auditors on the Standalone Unaudited Financial results for the Quarter and half year ended September 30, 2023.

Kindly take the same on your record and oblige us.

Thanking you

Yours faithfully,

For, Shree Ram Proteins Limited

leutensol

FOR SHREE RAM PROTEINS LIMITED.

MANAGING DIRECTOR.

Lalitkumar Chandulal (Vasova 6254) Chairman & Managing Director

DIN: 02296254

Place: Rajkot



SHREE RAM PROTEINS LTD.

Reg Off: B-206, The Imperial Heights, Opp. Big Bazaar, 150 Ft. Ring Road, Rajkot-360005, Gujarat, INDIA. Ph. +91 281 2581152

Fact: Survey No. 54 P, N.H. 27A, Nr. Pan Agri Exports At. Bhunava, Ta. Gondal,
Dist. Rajkot - 360311, Gujarat (INDIA) Ph.: +91 2825 280634 / 35
E-mail: shree_ramcotton@yahoo.com, info@shreeramproteins.com
web: www.shreeramproteins.com
Corporate Identity Number (CIN) L01405GJ2008PLC054913



Date: November 08, 2023

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra East, Mumbai-400051

Dear Sir,

Sub: Submission of Unaudited Standalone Financial Result of the Company for the Quarter and Half year ended on September 30, 2023 along with Limited Review Report.

Ref: Shree Ram Proteins Limited (Symbol:-SRPL, ISIN:- INE008Z01020)

In reference to captioned subject and pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Unaudited Standalone Financial Results of the Company for the Quarter and Half year ended on September 30, 2023 along with Limited Review Report issued by Statutory Auditors on the Unaudited Standalone Financial Results for the Quarter and Half year ended on September 30, 2023.

Kindly take the same on your record and disseminate the same on your website and oblige us.

Thanking You,

Yours faithfully,

For, Shree Ram Proteins Limited FOR SHREE RAM PROTEINS LIMITED.

Lalitkumar Chandular Vasova Rector. Chairman & Managing Director 254)

DIN: 02296254

leutesel

Place: Rajkot

Encl.:- A/a-

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

To
Board of Directors,
Shree Ram Proteins Limited

- 1. We have reviewed the accompanying statement of Unaudited Financial Results of **Shree Ram Proteins Limited** ("the Company") for the quarter and half year ended September 30, 2023 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
- 2. This Statement, which is the responsibility of the Company's management and has been approved by the Company's Board of Directors, has been compiled from the related financial statements which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder (Ind AS) and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review of such financial statements.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Basis for Adverse Opinion

Based on our review conducted as above, due to the matters stated at para 5 of this report, we believe that the accompanying Statement have not been prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting practices and principles generally accepted in India, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

M No. 42002

H. B. KALARIA & ASSOCIATES

A-601/602, The Imperial Heights, 150 Ft. Ring Road, Opp. Big Bazaar, Rajkot - 360 004.

- **5.** We draw your attention to the following matters:
 - i. Material uncertainty related to going concern status: We draw your attention to note. no. 7 of the financial statements where the Company has stated that the Company has defaulted in the repayment of its loans as well as payment of statutory dues (incl. CSR). The Company however continues to prepare its financial statements on a going-concern basis which is not in accordance with the provisions laid down in Ind-AS 1 Presentation of financial statements.
 - ii. We would like to draw your attention to note no. 8 of financial results, where the Company has made disclosures regarding ongoing Corporate Insolvency Resolution Process (CIRP) proceedings against the Company under The Insolvency and Bankruptcy Code, 2016. These conditions, along with the matters stated forth with indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern.
 - iii. The Company's management is responsible for carrying out the balance confirmation and reconciliations with various debtors, creditors, and advances. The Company has however not carried out any such balance confirmations and/or reconciliations with its debtors, creditors, and advances.
 - iv. The Company has not carried out an inspection of its inventories for the period under review. We are, hence, unable to carry out a review of the position of its inventories as the balance sheet date.
 - v. The Company has not carried out physical inspection of its property, plant and equipment for the period under review. We are, hence, unable to carry out a review of the position of its fixed assets as at the balance sheet date.
 - vi. The Company has not carried out an impairment assessment of its property, plant and equipment, inventories, advances, cash and bank balance and debtors. We are, hence, unable to provide an opinion on whether such balances reflect the true underlying economics of such balances.

Place: Rajkot

Date: 08/11/2023

For

HB Kalaria & Associates

Firm Reg. No. 104571W Chartered Accountants

(Hasmukh Kalaria)

Partner

Mem. No. 042002

UDIN:23042002BGVKVV5544

SHREE RAM PROTEINS LIMITED

Regd. Office: IMPERIAL HEIGHTS TOWER-B, SECOND FLOOR, OFFICE NO. B-206, 150 FT RING ROAD, OPP. BIG BAZAR, Rajkot, Gujarat, India, 360005

CIN: L01405GJ2008PLC054913

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2023

			Quarter Ended	i	Half Yea	ar Ended	Year Ended
	Particulars	30.09.2023 30.06.2023			30.09.2023 30.09.202		
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)		(Audited)
	INCOME						
I	Revenue from Operations	566.07	910.53	4,842.28	1,476.60	10,067.68	16,268.37
II	Other Income	22.68	10.24	3.16	32.92	3.19	5.11
III	Total Income (I+II)	588.75	920.77	4,845.44	1,509.52	10,070.87	16,273.47
	EXPENSES						
	Cost of materials consumed	759.61	267.90	3,854.76	1,027.51	7,483.81	12,569.65
IV	Purchases of stock-in-trade	-	-	399,91	-	567.08	593.75
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(133.73)	442.60	205.25	308.86	1,247.87	1,648.07
	Employee benefit expense	15.85	21.13	30.42	36.98	65.12	140.12
	Finance Costs	35.81	106.24	99.60	142.05	195.14	428.32
	Depreciation and amortisation expense	20.56	20.51	29.25	41.07	49.47	98.95
	Other Expenses	105.77	33.86	74.34	139.63	116.67	266.16
	Total Expenses (IV)	803.86	892.25	4,693.52	1,696.11	9,725.16	15,745.02
٧	Profit / (Loss) before exceptional items and tax (III-IV)	(215.10)	28.52	151.92	(186.58)	345.71	528.46
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/ (loss) after exceptions items and tax (V-VI)	(215.10)	28.52	151.92	(186.58)	345.71	528.46
	Tax Expense	(0.25)	0.26	F2 F0		407.50	457.60
VIII	(1) Current Tax (including tax expense of prior years) (2) MAT credit entitlement/availed	(9.36)	9.36	52.50	-	107.50	157.62
	(3) Deferred Tax	(16.49)	(1.43)	(3.50)	(17.92)	(1.15)	(13.69
IX	Profit / (Loss) for the period from continuing Operations(VII-VIII)	(189.25)	20.59	102.92	(168.66)	239.36	384.53
X	Profit/(Loss) from discontinuing Operation		-	-	-	-	-
XI	Tax Expense of discontinuing operations		-	-	-	-	-
XII	Profit / (Loss) from discontinuing continuing Operations (after tax) (X-XI)	-	-		-		-
XIII		(189.25)	20.59	102.92	(168.66)	239.36	384.53
	Other Comprehensive Income						
XIV	A. (i) Items that will not be reclassified to profit or loss	(0.11)	(0.11)	0.43	(0.22)	0.87	(0.44)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.02	0.03	(0.11)	0.05	(0.22)	0.11
VIA	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	_
	(ii)Income tax relating to items that will be reclassified to profit or loss	-		-	-	9	-
XV	Total Comprehensive Income for the period (XIII+XIV) {Comprising Profit (Loss) and Other	(189.33)	20.51	103.24	(168.82)	240.01	384.20
	comprehensive Income for the period } Paid-up Equity Share Capital (weighted Average)	2,142.00	2,142.00	2,142.00	2,142.00	2,142.00	2,142.00
	(Face Value Rs. 1 Each) Other equity excluding revaluation reserves	2,112.00	2,112.00	2,112.00	2/112.00	2/1 /2/00	3,465.29
VV/T							3,103.23
	Earnings per equity share (for continuing (1) Basic□	(0.09)	0.01	0.05	(0.08)	0.11	0.18
	(2) Diluted	(0.09)	0.01	0.05	(0.08)	0.11	0.18
(VII	Earnings per equity share (for discontinued operation)	(0.03)	0102	184-	(0.00)		
	(1) Basic□	-	_	-	-	-	-
	(2) Diluted	-	-	-	-	-	-
(VIII	Earning per equity share (for discontinued &						
	(1) Basic	(0.09)	0.01	0.05	(0.08)	0.11	0.18
		(0.00)					

FOR SHREE RAM PROTEINS LIMITED.

MANAGING DIRECTOR.
(DIN: 02296254)

Notes to the financial results:

- 1 The Company's financial results for the quarter and half year ended September 30, 2023 have been reviewed by the Audit Committee and subsequently approved & taken on record by the Board of Directors of the Company at its meeting held on 08th November, 2023.
- The Unaudited financial results for the quarter/half year ended September 30, 2023 have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of The Companies Act , 2013 and other recognised accounting practices and the policies to the extend applicable.
- 3 Figures of previous reporting periods have been regrouped/reclassified wherever necessary to correspond with the figures of the current reporting period.
- 4 The Statement of Assets and Liabilities as at September 30, 2023 is provided as an Annexure to this Statement.
- 5 Pursuant to insertion of new clause under Regulation 33, sub-regulation (3), the Company has prepared statement of cash flows for the half year ended
- During the year, the Company on 19 May 2023 ("Record Date") ,sub-divided/split of existing Equity Shares of the Company from 1(One) Equity Share having face value of Rs.10/-(Rupees Ten Only) each fully paid up, into 10 (Ten) Equity Share of the face value of Rs.1/- (One) each fully paid up. Accordingly, earnings per share of comparative periods presented has been calculated based on number of shares outstanding in respective periods,as increased by sub-divided/split of
- 7 The Company has defaulted in the repayment of its loans as well as the payment of its statutory dues in the period under review. The Company has withdrawn its Rights Issue on [25/08/2023] due to lack of investor interest. The Company is exploring all avenues to mitigate the current circumstances.
- The Corporate Insolvency Resolution Process (CIRP) proceeding has been initiated against the Company by NCLT, Ahmedabad bench with effect from 11.01.2023 under the provision of The Insolvency and Bankruptcy Code, 2016 for non payment of amount to one of the company's creditor. However, stay has been granted by National Company Law Appellate Tribunal Principal Bench, New Delhi, as on 25.01.2023 against above proceeding and ordered to pay amount of Rs. 1,21,82,419/- within two weeks of the order in the name of "The Pay and Accounts Officer, Ministry of Corporate Affairs, New Delhi"
- 9 The Company's Operations fall under a single segment "Solvent Products". Hence, Segment reporting is not applicable as per Indian Accounting Standard (Ind AS) 108 Segment Reporting.

For and on behalf of Board of Directors,

elverot

Lalitkumar Vasoya

Chariman & Managing Director DIRECTOR.
DIN -02296254 (DIN: 02296254)

Date: 08/11/2023 Place: Rajkot

SHREE RAM PROTEINS LIMITED

Regd. Office: IMPERIAL HEIGHTS TOWER-B, SECOND FLOOR, OFFICE NO. B-206, 150 FT RING ROAD, OPP. BIG BAZAR, Rajkot, Gujarat, India, 360005

CIN: L01405GJ2008PLC054913

UNAUDITED BALANCE SHEET AS AT 30TH SEPTEMBER 2023

(Rs. in lakhs)

A ASSETS 1 Non-Current Assets (a) Property, Plant & Equipment (b) Capital Work-in-Progress (c) Investment properties (d) Goodwill (e) Other intangible assets (f) Intangible assets under development (g) Biological Assets other than bearer plants (ii) Investments (iii) Loans (iv) Other financial asset (iii) Loans (iv) Other financial asset (i) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (i) Investments (ii) Trade Receivables (iii) Loans (iv) Other Ron-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (vi) Other Current Assets Sub-Total (Current Assets) TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity a) Equity Share Capital	30.09.2023 (Unaudited) 598.00	s at 31.03.2023 (Audited) 697.24 5.35 24.09 726.69 3,885.77 - 2,783.45 4.25 - 3,207.82 9,881.29
A ASSETS 1 Non-Current Assets (a) Property, Plant & Equipment (b) Capital Work-in-Progress (c) Investment properties (d) Goodwill (e) Other intangible assets (f) Intangible assets under development (g) Biological Assets other than bearer plants (h) Financial Assets (i) Investments (ii) Trade Receivables (iii) Loans (iv) Other financial asset (i) Deferred tax assets (net) (j) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (i) Investments (ii) Trade Receivables (ii) Trade Receivables (ii) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity a) Equity Share Capital	598.00 598.00	(Audited) 697.24 5.35
A Non-Current Assets a) Property, Plant & Equipment b) Capital Work-in-Progress c) Investment properties d) Goodwill e) Other intangible assets (i) Intangible assets under development g) Biological Assets other than bearer plants h) Financial Assets (ii) Investments (iii) Trade Receivables (iii) Loans (iv) Other financial asset (i) Deferred tax assets (net) j) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets a) Inventories b) Financial Assets (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets c) Current Tax Assets (Net) d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES B Equity a) Equity Share Capital	598.00	697.24 5.35
1 Non-Current Assets (a) Property, Plant & Equipment (b) Capital Work-in-Progress (c) Investment properties (d) Goodwill (e) Other intangible assets (f) Intangible assets under development (g) Biological Assets other than bearer plants (h) Financial Assets (i) Investments (ii) Trade Receivables (iii) Loans (iv) Other financial asset (i) Deferred tax assets (net) (j) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (v) Current Tax Assets (Net) (d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity a) Equity Share Capital		5.35
(a) Property, Plant & Equipment (b) Capital Work-in-Progress (c) Investment properties (d) Goodwill (e) Other intangible assets (f) Intangible assets under development (g) Biological Assets other than bearer plants (h) Financial Assets (i) Investments (ii) Investments (iii) Loans (iv) Other financial asset (i) Deferred tax assets (net) (j) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (i) Investments (ii) Investments (ii) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (v) Loans & Advances (vi) Other Financial Assets (vi) Other Current Assets Sub-Total (Current Assets) TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity a) Equity Share Capital		5.35
(b) Capital Work-in-Progress (c) Investment properties (d) Goodwill (e) Other intangible assets (f) Intangible assets under development (g) Biological Assets other than bearer plants (ii) Investments (ii) Investments (iii) Loans (iv) Other financial asset (i) Deferred tax assets (net) (j) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets Sub-Total (Current Assets) TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity a) Equity Share Capital		5.35
(c) Investment properties (d) Goodwill (e) Other intangible assets (f) Intangible assets under development (g) Biological Assets other than bearer plants (h) Financial Assets (i) Investments (ii) Trade Receivables (iii) Loans (iv) Other financial asset (j) Deferred tax assets (net) (j) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity a) Equity Share Capital	8,96 73,37 680,34 3,934,86 2,748,51 16,16	
d) Goodwill (e) Other intangible assets (f) Intangible assets under development (g) Biological Assets other than bearer plants (h) Financial Assets (i) Investments (ii) Trade Receivables (iii) Loans (iv) Other financial asset (i) Deferred tax assets (net) (i) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivalents (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity a) Equity Share Capital	8,96 73,37 680.34 3,934.86 2,748.51 16.16	
(e) Other intangible assets (f) Intangible assets under development (g) Biological Assets other than bearer plants (h) Financial Assets (i) Investments (ii) Trade Receivables (iii) Loans (iv) Other financial asset (i) Deferred tax assets (net) (j) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets a) Inventories b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity a) Equity Share Capital	8,96 73,37 680.34 3,934.86 2,748.51 16.16	
(f) Intangible assets under development (g) Biological Assets other than bearer plants (h) Financial Assets (i) Investments (ii) Trade Receivables (iii) Loans (iv) Other financial asset (i) Deferred tax assets (net) (j) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (i) Investments (ii) Trade Receivables (ii) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity a) Equity Share Capital	3,934.86 3,934.86 2,748.51 16.16	24.09 726.69 3,885.77 2,783.45 4.25 3,207.82 9,881.29
(g) Biological Assets other than bearer plants (h) Financial Assets (i) Investments (ii) Trade Receivables (iii) Loans (iv) Other financial asset (i) Deferred tax assets (net) (j) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	3,934.86 3,934.86 2,748.51 16.16	24.09 726.69 3,885.77 - 2,783.45 4.25 - 3,207.82 9,881.29
(h) Financial Assets (i) Investments (ii) Trade Receivables (iii) Loans (iv) Other financial asset (i) Deferred tax assets (net) (j) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	3,934.86 3,934.86 2,748.51 16.16	24.09 726.69 3,885.77 2,783.45 4.25 -
(i) Investments (ii) Trade Receivables (iii) Loans (iv) Other financial asset (i) Deferred tax assets (net) (j) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	3,934.86 2,748.51 16.16 - 3,274.30 9,973.83	24.09 726.69 3,885.77 2,783.45 4.25 3,207.82 9,881.29
(ii) Trade Receivables (iii) Loans (iv) Other financial asset (i) Deferred tax assets (net) (j) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	3,934.86 2,748.51 16.16 - 3,274.30 9,973.83	24,09 726.69 3,885.77 2,783.45 4.25 3,207.82 9,881.29
(iii) Loans (iv) Other financial asset (i) Deferred tax assets (net) (j) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	3,934.86 2,748.51 16.16 - 3,274.30 9,973.83	24.09 726.69 3,885.77 - 2,783.45 4.25 - 3,207.82 9,881.29
(iv) Other financial asset (i) Deferred tax assets (net) (j) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	73.37 680.34 3,934.86 2,748.51 16.16 - 3,274.30 9,973.83	24.09 726.69 3,885.77 - 2,783.45 4.25 - 3,207.82 9,881.29
(i) Deferred tax assets (net) (j) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	73.37 680.34 3,934.86 2,748.51 16.16 - 3,274.30 9,973.83	24.09 726.69 3,885.77 - 2,783.45 4.25 - 3,207.82 9,881.29
(i) Other Non-Current Assets Sub-Total (Non-Current Assets) 2 Current Assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets Sub-Total (Current Assets) TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	73.37 680.34 3,934.86 2,748.51 16.16 - 3,274.30 9,973.83	3,885.77 - 2,783.45 4.25 - 3,207.82 9,881.29
Sub-Total (Non-Current Assets) 2 Current Assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets Sub-Total (Current Assets) TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	3,934.86 	3,885.77 - 2,783.45 4.25 - 3,207.82 9,881.29
2 Current Assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets Sub-Total (Current Assets) TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	3,934.86 - 2,748.51 16.16 - 3,274.30 9,973.83	3,885.77 - 2,783.45 4.25 - 3,207.82 9,881.29
(a) Inventories (b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	2,748.51 16.16 - - 3,274.30 9,973.83	2,783.45 4.25 - 3,207.82 9,881.29
(a) Inventories (b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	2,748.51 16.16 - - 3,274.30 9,973.83	2,783.45 4.25 - 3,207.82 9,881.29
(b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	2,748.51 16.16 - - 3,274.30 9,973.83	2,783.45 4.25 - 3,207.82 9,881.29
(i) Investments (ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	2,748.51 16.16 - - - 3,274.30 9,973.83	3,207.82 9,881.29
(ii) Trade Receivables (iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	2,748.51 16.16 - - - 3,274.30 9,973.83	3,207.82 9,881.29
(iii) Cash & Cash equivalents (iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets Sub-Total (Current Assets) TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	3,274.30 9,973.83	3,207.82 9,881.29
(iv) Bank Balances other than cash & Cash equivelants (v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets Sub-Total (Current Assets) TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	3,274.30 9,973.83	3,207.82 9,881.29
(v) Loans & Advances (vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets Sub-Total (Current Assets) TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	3,274.30 9,973.83	9,881.29
(vi) Other Financial Assets (c) Current Tax Assets (Net) (d) Other Current Assets Sub-Total (Current Assets) TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	9,973.83	9,881.29
(c) Current Tax Assets (Net) (d) Other Current Assets Sub-Total (Current Assets) TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	9,973.83	9,881.29
Moder Current Assets Sub-Total (Current Assets) TOTAL ASSETS (1+2) B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	9,973.83	9,881.29
B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	9,973.83	9,881.29
B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital		
B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	10,654.17	10.507.07
B EQUITY AND LIABILITIES 3 Equity (a) Equity Share Capital	10,054.17	
3 Equity (a) Equity Share Capital		10,607.97
3 Equity (a) Equity Share Capital		
(a) Equity Share Capital		
	2,142.00	2,142.00
b) Other Equity	3,296.46	3,465.29
by Todier Equity	5,250.40	5,705.25
Sub-Total (Equity)	5,438.46	5,607.29
Liabilities	3,430.40	5,007.29
4 Non-Current Liabilities		
a) Financial Liabilities		
	924 50	775.70
(i) Long-Term Borrowings	831.59	//3./0
(ii) Trade Payable		-
(iii) Other Financial Liabilities	12.20	10.76
b) Provisions	12.26	10.76
(c) Deferred Tax Liabilities (Net)		9.02
d) Other non-current liabilities	042.05	705 47
Sub-Total (Non-Current Liabilities)	843.85	795.47
5 Current Liabilities	200	-
(i) Short town Removings	2 005 44	2010.05
(i) Short-term Borrowings	2,885.41	2,919.05
(ii) Trade Payables		
(A) total outstanding dues of micro enterprises and small		
enterprises; and	044.64	047.05
(B) total outstanding dues of creditors other than micro	941.64	817.05
enterprises and small enterprises.	T. 40	
(iii) Other Financial Liabilities	71.69	52.63
b) Other Current Liabilities	92.51	40.62
c) Provisions	17.03	11.72
d) Current Tax Liabilities (Net)	363.56	364.14
Sub-Total (Current Liabilities)	4,371.86	4,205.21
TOTAL EQUITY AND LIABILITIES (3+4+5)	10,654.17	10,607.97

FOR STATE OF BOHALFOR BOARD SPIRESTONS D.

Lalitkumar Vasoya MANAGING

Lalitkumar Vasoya MANAGING DIRECTOR.
Chariman & Managing Direct 2296254)
DIN -02296254

Date: 08/11/2023 Place: Rajkot

SHREE RAM PROTEINS LIMITED

Regd. Office: IMPERIAL HEIGHTS TOWER-B, SECOND FLOOR, OFFICE NO. B-206, 150 FT RING ROAD, OPP. BIG BAZAR, Rajkot, Gujarat, India, 360005

CIN: L01405GJ2008PLC054913

Statement of Unaudited Cash Flow for the Half Year Ended 30th September, 2023

(Rs. in lakhs)

	Particulars	For the period ended September 30, 2023	For the period ended Mach 31, 2023
A.	Cash Flow from Operating Activity		7.00
	Net Profit Before Tax	(186.58)	528.46
	Adjustments For:		
	Depreciation	41.07	98.95
	Interest & Financial Expenses	142.05	428.32
	(Gain)/Loss on Sales of Assets	(25.48)	-
	Interest Received on Deposits	(0.02)	(0.87)
	Provision for Gratuiry	1.72	3.44
	Provision for Doubtful Debts	61.01	25.78
	Provision for CSR Exepenses	4.87	8.56
	Bad debt	-	3.83
		225.22	568.02
	Operation profit before Working Capital Changes	38.64	1096.48
	Adjustment For:		
	Changes in Current Assets		
	Inventories	(49.10)	2370.34
	Trade Receivables	(26.07)	(2010.96)
	Other Asset	(115.76)	(2495.30)
	Trade Payables & Other Liabilities and Provisions	195.55	(994.69)
	Taxes Paid	(0.58)	14.14
		4.04	(3116.47)
	Cash Generated from Operations	42.68	(2020.00)
B.	Cash Flow from Investment Activities		
	Proceeds from disposal of Property, Plant and Equipments	89.25	-
	Purchase of Property, Plant and Equipments	(0.25)	(124.76)
	Redemption of Investments	- 1	0.00
	Interest Received	0.03	0.87
	Net Cash Flow from Investment Activities	89.03	(123.89)
C.	Cash Flow from Financial Activities:		
	Changes in Long-term borrowings (net)	55.90	(269.02)
	Changes in Short-term borrowings (net)	(33.64)	(287.67)
	Interest & Financial Expenses	(142.05)	(428.32)
	Net Cash Flow from Financial Activities	(119.79)	(985.01)
	Total of Cash Flow (A+B+C)	11.92	(3128.90)
	Cash & Cash Equivalent at the beginning of the year	4.25	3133.15
	Cash & Cash Equivalent at the ending of the year	16.16	4.25
	Cash & Cash Equivalent compriging of		
	Cash on Hand	6.11	4.22
	Balances with Scheduled Banks	10.04	0.02
		16.16	4.25

FOR For and on behalf of Board of Directors,

MANAGING DIRECTOR.
Lalitkumar Vasoya N: 02296254)
Chariman & Managing Director

DIN -02296254

lectron

Date: 08/11/2023 Place: Rajkot